STEP 4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Archive — June 2026
Page 3 of 5 of this archive, newest first.
The withdrawal trials, read as designs rather than warnings
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Background rates, and why they matter for attribution
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What changed at SWB in June, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What a laboratory knows about the material it receives
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.
Two per cent water sounds like nothing and is not nothing
Residual moisture is measured routinely in regulated manufacture, is reported almost nowhere in this trade, and predicts long-term stability better than any other single…
Saudi Arabia health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
SURPASS-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 16 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The consolidator trading as Meridian Freight Partners enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
The eighteenth month, and the conversation that should have happened in the third
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
The badge is about a sample. The listing is about a product.
The Journal does not treat a badge as evidence and states so wherever it reports one.
In-use periods, and the ones nobody can give you
A needle blunts on first use. Reuse is uncomfortable, and it is a documented contributor to lipohypertrophy.
SURPASS-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a QYB semaglutide lot at 98.3%, against 96.3% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
From the floor in Chengdu: 20 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
What the outcome trials measured in the kidney
Asymptomatic pancreatic enzyme elevation is common on treatment and is not pancreatitis. The distinction is clinical, not biochemical.
FLOW extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Poland pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
Do you need the top of the ladder?
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
How far back does this document actually reach?
A document is only as good as the chain that connects it to the material, and most chains here are two or three links longer than the paperwork admits.
What the new South Korea guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The relabeller trading as Vantris Bio closes after 5 years
A proper account of an operation that existed, and of what closing it cost.
The relabeller trading as Vantris Bio closes after 23 years
A proper account of an operation that existed, and of what closing it cost.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
The instrument was calibrated on Tuesday. Your sample ran on Friday.
Calibration drift is real, unremarkable, and the reason serious laboratories run internal standards.
The one randomised trial that combined an incretin with supervised exercise
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
Why a 0.036-dalton difference is the hardest number in peptide identity
Every instrument specification quoted in an advertisement is a best case obtained on a calibration mixture, not on a submitted vial.
The quiet end of the consolidator trading as Meridian Freight Partners
A proper account of an operation that existed, and of what closing it cost.
New Zealand declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Changsha export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
The shortage years, and what they taught about interruption
The trials studied planned withdrawal. Almost nobody stops that way.
Inspectors cite the online reseller trading as Adamant Research Supply over sterility assurance
The observation that closes a facility is rarely the dramatic one.
France caps semaglutide prescribing to 3 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
SURPASS-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.